Literature DB >> 10603626

Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands.

M P Rutten-van Mölken1, M J Postma, M A Joore, M L Van Genugten, R Leidl, J C Jager.   

Abstract

The aim of this study was to estimate the healthcare costs of asthma and chronic obstructive pulmonary disease (COPD), in the Netherlands, in 1993. Also studied was the future development of these costs, as a result of ageing and possible changes in smoking behavior. A prevalence-based cost-of-illness approach was used to estimate direct medical costs. Age- and gender-specific data were obtained from representative national registries and large, representative surveys. To model future costs, cost estimates were linked to an epidemiological model based on a dynamic multi-state lifetable. It describes 1 yr changes, from one state to another, that result from ageing, birth, migration, incidence, recovery from asthma and death due to asthma, COPD or other causes, and starting or quitting smoking. Three different scenarios were modelled: 1) a reference scenario which primarily predicts the impact of ageing. 2) an 'attainable' smoking reduction scenario and 3) an 'extreme' smoking reduction scenario. Direct medical costs were estimated to be $US 346 million in 1993. With increasing age, the relative importance of asthma in total asthma and COPD costs decreased from 91% to less than 4%. Annual costs per patient were estimated to be $US 499 for asthma and $US 876 for COPD. The breakdown of costs differed considerably between asthma and COPD. The reference scenario predicted the costs to increase by 60% to reach $US 555 million by 2010, COPD prevention as modelled in the second and the third scenario reduced the projected cost increase from 60%, to 57% and 48%, respectively. Together, the direct costs of asthma and COPD represent 1.3% of the Dutch health care budget. The breakdown of the costs shows different patterns for asthma and COPD. The costs of these diseases are expected to increase by 60% in the near future. In the short run the impact of smoking reduction on reducing this increase is relatively small, but it will be greater in the long run.

Entities:  

Mesh:

Year:  1999        PMID: 10603626     DOI: 10.1016/s0954-6111(99)90262-7

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  16 in total

Review 1.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.

Authors:  Björn Stollenwerk; Thomas Welchowski; Matthias Vogl; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2015-02-04

Review 4.  An economic overview of chronic obstructive pulmonary disease.

Authors:  H S Ruchlin; E J Dasbach
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands.

Authors:  M P Rutten van-Mölken; T L Feenstra
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  AsthmaCritic: issues in designing a noninquisitive critiquing system for daily practice.

Authors:  Manon M Kuilboer; Marc A M van Wijk; Mees Mosseveld; Johan van der Lei
Journal:  J Am Med Inform Assoc       Date:  2003-06-04       Impact factor: 4.497

Review 7.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

8.  Risk factors of hospitalization and readmission of patients with COPD in Hong Kong population: analysis of hospital admission records.

Authors:  Frank W K Chan; Fiona Y Y Wong; Carrie H K Yam; Wai-ling Cheung; Eliza L Y Wong; Michael C M Leung; William B Goggins; Eng-kiong Yeoh
Journal:  BMC Health Serv Res       Date:  2011-08-10       Impact factor: 2.655

9.  The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Sevket Ozkaya; Serhat Findik; Atilla Guven Atici
Journal:  Clinicoecon Outcomes Res       Date:  2011-01-17

Review 10.  Airways inflammation and treatment during acute exacerbations of COPD.

Authors:  Erik Bathoorn; Huib Kerstjens; Dirkje Postma; Wim Timens; William MacNee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.